Luca Massacesi
Professor
Department of Neuroscience, Psychology, Area of ​​Medici
University of Florence
Italy
Biography
Italian Multiple Sclerosis Society (AISM); member of the Scientific Committee / Research Evaluation Committee. 1994-1997 - R & D program of the DG XII EU Commission Project Leader of the Concerted Action: "T-cell Autoimmunity in Multiple Sclerosis". 1997-1999 - Multicenter Italian Study of the Italian Multiple Sclerosis Association (AISM): "Centralized Facility for Genetic Studies in Multiple Sclerosis." Coordinator. 1999-2000 - International Federation of Multiple Sclerosis Societies: Scientific Program Committee; member of the Medical Advisory Board. 1995-2001 - Biomedical Primate Research EU Large Scale Facility, Rijswijk, The Nederland; member of the Scientific Committee. 1998-2002 - Italian multicenter clinical trial: "Open randomized clinical study on different doses of bIFN1a, also in association with Azathioprine, in patients with relapsing remitting multiple sclerosis": National Scientific Coordinator. 2010-2012 - Data and Safety Monitoring Board (DSMB) of the National Institutes of Health (NIH) phase II intramural clinical study: "Investigating mechanism of action of DAC HYP (Daclizumab) in the treatment of high inflammatory multiple sclerosis": Chairman. 2006-2011 - Multicenter non-profit clinical trials funded by the Italian Agency for Medicinal Products (AIFA) "Randomized controlled study of Azathioprine versus Interferon beta in relapsing-remitting multiple sclerosis". National Scientific Coordinator. 2009-present - European Medicines Agency (EMA), London, UK; Scientific Advisory Group - Neurology, member. 2009-present - Italian Medicines Agency (AIFA), Rome, Italy; Scientific Advisory Committee on
Research Interest
Clinical Neurology, Neuroimmunology, Inflammatory diesases of the Nervous System, Imaging of the Nervous System.
Publications
-
Maggi, Pietro; Sati, Pascal; Massacesi, Luca (2016). Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset.. JOURNAL OF NEUROIMMUNOLOGY, vol. 304, pp. 86-92, ISSN:0165-5728
-
Forci, B; Mariottini, A; Mechi, C; Massacesi, L; Repice, A. (2017). Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.. MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol. 15, pp. 24-26, ISSN:2211-0348
-
Muraro, P.A.; Pasquini, ; M, .; Atkins, ; Hl, H.L.; Bowen, ; Jd, J.D.; Farge, ; D, .; Fassas, ; A, .; Freedman, ; Ms, M.S.; Georges, ; Ge, G.E.; Gualandi, ; F, .; Hamerschlak, ; N, .; Havrdova, ; E, .; Kimiskidis, ; Vk, V.K.; Kozak, ; T, .; Mancardi, ; Gl, G.L.; Massacesi, ; L, .; Moraes, ; Da, D.A.; Nash, ; Ra, R.A.; Pavletic, ; S, .; Ouyang, ; J, .; Rovira, ; M, .; Saiz, ; A, .; Simoes, ; B, .; Trněný, ; M, .; Zhu, ; L, .; Badoglio, ; M, .; Zhong, ; X, .; Sormani, ; Mp, M.P.; Saccardi, (2017). Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.. JAMA NEUROLOGY, vol. 74, pp. 459-469, ISSN:2168-6149
